Researchers at the University of Manchester have secured nearly 1 million pounds to develop soft robots modeled on snail biology, with the goal of delivering cancer drugs directly to bowel tumors while sparing healthy tissue. The project sits at the intersection of two fast-moving research tracks: bioinspired locomotion and magnetically guided microrobots designed to operate inside the human gastrointestinal tract. If the prototypes work as intended, they could offer a radically different approach to treating colorectal cancer, one of the most common and deadly cancers worldwide.
Why Snails, and Why Now
Snail locomotion has attracted scientific attention for years because these animals can traverse wet, uneven, and slippery surfaces with remarkable control. That ability maps well onto the conditions inside the human intestine, where any drug delivery device must contend with mucus, peristaltic motion, and sharp pH changes between the stomach and colon. A recent highlight in Nature documented how a self-healing gel enabled a robotic snail to slither across challenging surfaces, demonstrating that snail-inspired materials could survive and function in environments that destroy conventional rigid robots.
Carnegie Mellon University engineers built on that principle with an untethered snail-like soft robot carrying an embedded battery and motor, showcasing a self-healing conductive material that maintained measurable performance even after being severed and reconnected. That resilience matters because any device traveling through the gut will face mechanical stress, chemical attack, and repeated deformation.
The Manchester team is now applying these biological insights to cancer treatment specifically. According to the project description in the university’s Research Explorer, the work aims to generate new data on snail biomechanics and use it to accelerate the design of soft robots for high-precision drug delivery. The robots would be constructed from peptide-based biomaterials, and the stated goal is to demonstrate prototypes that can assist in treating colorectal cancer by navigating to diseased sites and releasing drugs locally.
How Microrobots Navigate the Gut
The snail-inspired effort does not exist in isolation. Several research groups have already shown that tiny robots can be guided through intestinal environments using magnetic fields, and that protective coatings can shield therapeutic payloads from stomach acid until the device reaches its target.
A paper in Biomaterials describes an intestinal therapeutic agent delivery microrobot, known as ITAM, built around a core-shell architecture that combines magnetic guidance with pH-responsive degradation. The protective shell is designed to survive the acidic stomach environment, then break down at the higher pH levels found near intestinal lesions, releasing its therapeutic cargo precisely where needed. The authors frame the platform explicitly for colorectal cancer applications, arguing that such microrobots could concentrate drugs at tumor sites while reducing systemic exposure.
A separate study reported in Advanced Materials takes a different route: an oral biohybrid microrobot enclosed in enteric-coated capsules that exploit tumor-related conditions in the gastrointestinal tract. The device combines biological components with synthetic materials and is designed to overcome barriers such as mucus and fluid flow, enabling localized action in the intestinal tract. Like ITAM, this system remains in the preclinical stage, but it adds to the evidence that orally administered microrobots can survive transit through the upper GI tract and become active only when they reach diseased tissue.
From Pig Intestines to Proof of Concept
The most detailed experimental demonstration so far comes from a collaboration involving Oxford and Michigan researchers. Their magnetically actuated soft microrobots, roughly 0.2 mm in size, were tested in a pig-intestine model that mimics the conditions of a living human gut. The workflow involved introducing the robots via catheter, guiding them with external magnets to target sites, dissolving a gel layer to release cargo, and then retrieving the robots afterward using the same magnetic control.
That retrieval step is significant because it means the device does not remain inside the body, reducing the risk of long-term complications or chronic inflammation. In coverage distributed through EurekAlert, researcher Molly Stevens emphasized that the platform allows programmable cargo delivery and post-treatment recovery of the microrobots, pointing to a potential path toward safer clinical translation.
The underlying study, detailed in a Science Advances paper archived by the University of Oxford, reports that the soft robots could be steered in real time through complex intestinal geometries while maintaining control over when and where their payloads were released. The authors contrast this approach with systemic intravenous delivery, where only a small fraction of a drug dose reaches the tumor and the rest circulates through healthy organs, driving side effects.
The Case Against Systemic Chemotherapy
Standard chemotherapy for bowel cancer floods the entire body with toxic drugs to reach a tumor that may occupy only a few centimeters of tissue. The side effects, from nausea and immune suppression to nerve damage, are well documented and often force patients to reduce doses or abandon treatment altogether. The Manchester project documentation states directly that its goal is to reduce the side effects of these toxic drugs by localizing delivery, ideally allowing higher effective doses at the tumor and lower exposure elsewhere.
Targeted approaches using stimuli-responsive carriers have been explored in parallel to microrobots. A review of endogenous stimuli-responsive liposomes as advanced nanocarriers notes that some formulations aim to enhance treatment by triggering localized membrane disruption, even when they do not encapsulate a conventional chemotherapeutic agent. In those systems, the delivery mechanism itself contributes to tumor damage, for example by destabilizing cancer cell membranes in response to pH or redox changes.
Microrobot researchers are building on similar principles by combining physical navigation with environment-sensitive release triggers. A robot that can crawl or glide along the intestinal wall, sense local pH or enzyme levels, and then open its drug reservoirs only under tumor-specific conditions could, in theory, concentrate therapy where it is most needed. The snail-inspired designs add another layer: mechanical conformity to soft, mucus-covered tissue, which may improve contact and retention at lesion sites.
What Remains Unproven
For all the progress, significant gaps separate these prototypes from routine use in oncology clinics. Most of the work to date has been conducted in vitro or in animal models such as pig intestines, which, while anatomically similar to humans, do not capture the full complexity of human immune responses, microbiome interactions, or long-term safety concerns. No snail-inspired soft robot has yet been tested in human patients, and the Manchester team’s goals remain firmly in the research phase.
Biocompatibility is one major unknown. Peptide-based biomaterials and self-healing gels must not only perform mechanically but also avoid provoking immune reactions or breaking down into harmful byproducts. Regulatory agencies will require extensive toxicology and biodistribution data before approving any device that travels through, and potentially adheres to, the intestinal lining. Retrieval strategies, like those demonstrated in the Oxford-Michigan work, may ease those concerns but will need to be adapted to different robot sizes and materials.
Control and imaging pose additional challenges. External magnetic fields can steer microrobots in relatively simple experimental setups, yet human anatomy, motion, and variability in tissue density complicate precise navigation. Real-time imaging methods, whether based on fluoroscopy, MRI, or other modalities, must be accurate enough to track tiny devices without exposing patients to excessive radiation or cost. Integrating these guidance systems into busy clinical workflows remains an open problem.
Manufacturing and scalability are also unresolved. The intricate structures described in current publications are typically fabricated in small batches under laboratory conditions. To become medically and economically viable, soft microrobots will have to be produced reproducibly at scale, with tight control over size, payload, and degradation behavior. Any variability could translate into inconsistent dosing or unpredictable clearance from the body.
Finally, there is the question of clinical benefit. Even if snail-inspired robots can deliver drugs precisely to bowel tumors, researchers will need robust trials comparing outcomes against existing standards of care, including modern systemic regimens and non-robotic targeted delivery systems. Measures such as tumor response, survival, quality of life, and cost-effectiveness will determine whether these devices move beyond experimental curiosity.
For now, the Manchester project and related microrobot efforts represent a bold attempt to rethink how cancer drugs reach their targets. By blending insights from snail biomechanics, smart materials, and magnetic navigation, they hint at a future in which therapy is not merely injected or infused but actively piloted through the body to the cells that need it most. Whether that vision becomes routine practice will depend on how convincingly researchers can bridge the gap between elegant laboratory demonstrations and the messy realities of human disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
